Log In Sign up
The largest database of trusted experimental protocols
> Procedures > Laboratory Procedure > Comprehensive Metabolic Panel

Comprehensive Metabolic Panel

The Comprehensive Metabolic Panel (CMP) is a common laboratory test that provides a comprehensive assessment of a person's metabolic status.
It measures a variety of serum chemicals and electrolytes, including glucose, kidney and liver function markers, and other key metabolic indicators.
The CMP is often used as a screening tool to evaluate overall health and detect potential imbalances or underlying medical conditions.
Clinicians may order a CMP as part of a routine checkup or to investigate specific symptoms or concerns.
The test results can provide valuable insights into a patient's metabolic profile and help guide further diagnostic evaluation and treatment planning.
Optimizing CMP research through techniques like PubCompare.ai can enhance the reproducibility and accuracy of these important clinical measurements.

Most cited protocols related to «Comprehensive Metabolic Panel»

1
Predicting Thiopurine Response in IBD
The study sample included all patients who had thiopurine metabolite analysis, complete blood count, and a comprehensive chemistry panel drawn within a 24 hour period at the University of Michigan between 1 May 2004 and 31 August 2006 and is described in greater detail in the manuscript.1 (link) This study was approved by the University of Michigan Medical Institutional Review Board with a waiver of explicit consent from the participants. The patient sample included 774 cases in a total of 346 individuals. For the analysis of the outcome of clinical response to thiopurines, 5 exclusion criteria were applied: exclusion of patients who did not have IBD, exclusion of patients who had not started on thiopurines at the time when the metabolites were measured, exclusion of patients on biological antitumour necrosis factor therapy, exclusion of patients without documentation of their clinical status at the time of laboratory measurement, and exclusion of patients who had an infection that confounded assessment of clinical response. This data set was used as the basis of a predictive model to identify patients with clinical response to thiopurine immune suppressant medication with a c statistic of 0.86.1 (link)
Waljee A.K., Mukherjee A., Singal A.G., Zhang Y., Warren J., Balis U., Marrero J., Zhu J, & Higgins P.D. (2013). Comparison of imputation methods for missing laboratory data in medicine. BMJ Open, 3(8), e002847.
Publication 2013
Complete Blood Count Comprehensive Metabolic Panel Ethics Committees, Research Immunosuppressive Agents Infection Necrosis Patients Pharmaceutical Preparations Therapies, Biological
2
Lifetime Cohort Study of Pediatric Cancer Survivors
Following provision of written informed consent, eligible survivors were enrolled in the ongoing IRB-approved St. Jude Lifetime Cohort Study (SJLIFE) using recruitment strategies described previously.6 (link),7 (link) The objective of the SJLIFE study is to establish a lifetime cohort of survivors treated at St. Jude Children’s Research Hospital (SJCRH) to facilitate prospective periodic medical assessment of health outcomes among adults surviving pediatric malignancies. Eligibility for SJLIFE includes attained age of 18 years or older, treatment for cancer at SJCRH, and survival 10 or more years post diagnosis. The order of recruitment of eligible survivors was randomly determined by allocating subjects to blocks of size 50. This study included participants who were within the first 59 consecutive recruitment blocks (Supplemental Figure 1). Through the 59th recruitment block, 2888 survivors were potentially eligible. Of 2843 confirmed eligible, 1837 (64.6%) enrolled in the study. This analysis included 1713 participants (60.3% of eligible) diagnosed and treated between 1962 and 2001, enrolled on study since 10/01/2007, and followed until 10/31/2012, who had completed on-campus medical evaluations. Non-participants included 680 who actively or passively elected not to participate, 277 who expressed interest in participating but had not completed their campus visit, 124 who completed questionnaires but did not receive on-campus medical assessment, and 49 who were lost to follow-up.
Medical record abstraction documented the type and cumulative doses of treatment, information on surgical interventions, acute life-threatening organ toxicities, primary cancer recurrences, chronic health conditions, and subsequent neoplasms. Race and ethnicity were self-reported by participants and ascertained for non-participants by administrative record review of race/ethnicity reported by parents at diagnosis. Participants completed comprehensive health questionnaires prior to their clinical assessment. All participants underwent a core battery of evaluations comprised of history and physical examination with resting heart rate, blood pressure, 12-lead electrocardiography, and laboratory studies including complete blood count/differential, comprehensive metabolic panel, fasting lipid profile, insulin and hemoglobin A1C, assessments of thyroid and gonadal function, urinalysis, and a comprehensive physical performance assessment including measurement of body composition and neuromuscular system integrity. Participation also involved a clinical evaluation consistent with the risk-based screening and surveillance recommended by the Children’s Oncology Group (COG Guidelines).8 The risk-based portion of the assessment included additional laboratory tests and evaluations of organ function (e.g., echocardiography, pulmonary function testing, audiological testing, ophthalmology evaluation, neurocognitive testing, bone mineral density testing).
Hudson M.M., Ness K.K., Gurney J.G., Mulrooney D.A., Chemaitilly W., Krull K.R., Green D.M., Armstrong G.T., Nottage K.A., Jones K.E., Sklar C.A., Srivastava D.K, & Robison L.L. (2013). Clinical Ascertainment of Health Outcomes among Adults Treated for Childhood Cancer: A Report from the St. Jude Lifetime Cohort Study. JAMA : the journal of the American Medical Association, 309(22), 2371-2381.
Publication 2013
Adult Blood Pressure Bone Density Child Chronic Condition Complete Blood Count Comprehensive Metabolic Panel Diagnosis Echocardiography Electrocardiography, 12-Lead Eligibility Determination Ethnicity Gonads Health Risk Assessment Hemoglobin A, Glycosylated Insulin Lipids Malignant Neoplasms Measure, Body Neoplasms Operative Surgical Procedures Parent Physical Examination Rate, Heart Recurrence Survivors Thyroid Gland Urinalysis
3
Randomized Trial of Menopausal Hormone Therapy
KEEPS was designed as a randomized, placebo-controlled, double-blinded, prospective trial (KEEPS; NCT000154180) to evaluate effects of MHT on progression of atherosclerosis as defined by carotid intima–media thickness (CIMT) [44 (link)] and coronary arterial calcification (CAC) [8 (link), 73 (link)] in women who more closely match the age of initiation of MHT reported by prior observational studies. Women meeting inclusion criteria subsequently were randomized to daily placebo, oral CEE, or transdermal 17β-estradiol with placebo or pulsed progesterone for 12 days/month. The detailed inclusion and exclusion criteria for KEEPS have been published elsewhere [36 (link)]. In brief, women between the ages of 42 and 58 years of age who were at least 6 months and no more than 36 months from their last menses with plasma follicle-stimulating hormone (FSH) level ≥35 ng/mL and/or E2 levels <40 pg/mL were eligible. A history of clinical CVD including myocardial infarction, angina, congestive heart failure, or thromboembolic disease excluded women from KEEPS. Other major cardiovascular risk factors excluding participation were current heavy smoking (more than ten cigarettes/day by self-report), morbid obesity [body mass index (BMI) >35 mm2/kg], dyslipidemia (LDL cholesterol >190 mg/dL), hypertriglyceridemia (triglycerides >400 mg/dL), and uncontrolled hypertension (systolic blood pressure >150 mm Hg and/or diastolic blood pressure >95 mm Hg) and glucose >126 mg/dL. Complete blood count and chemistry panel, estradiol, and FSH were performed at the clinical laboratories at each recruiting center. Lipid profiles and thyroid-stimulating hormone (TSH) were performed at the Kronos Science Laboratories (Phoenix, AZ, USA). At screening, women were asked to rank their menopausal symptoms (hotflashes, night sweats, vaginal dryness, dyspareunia, palpitations, insomnia, depression, mood swings, and irritability) as either none, mild, moderate, or severe. Finally, all subjects were screened for CAC and women with Agatston score ≥50 U, indicating significant subclinical coronary artery disease, were excluded. All women meeting inclusion criteria underwent baseline measurements of CIMT by B-mode ultrasound [44 (link)]. All imaging results are read centrally by individuals blinded to participant demographics (CAC at the Los Angeles Biomedical Research Institute at Harbor-UCLA, Torrance, CA, USA under the direction of Dr. M. Budoff and CIMT at the Atherosclerosis Research Unit Core Imaging and Reading Center, University of Southern California, Los Angeles, CA, USA under the direction of Dr. H. Hodis).
Analysis of variance was used to determine statistical significance except where an alternative test is specified. Statistical significance was accepted at P < 0.05.
Miller V.M., Black D.M., Brinton E.A., Budoff M.J., Cedars M.I., Hodis H.N., Lobo R.A., Manson J.E., Merriam G.R., Naftolin F., Santoro N., Taylor H.S, & Harman S.M. (2009). Using Basic Science to Design a Clinical Trial: Baseline Characteristics of Women Enrolled in the Kronos Early Estrogen Prevention Study (KEEPS). Journal of Cardiovascular Translational Research, 2(3), 228-239.
Publication 2009
Angina Pectoris Artery, Coronary Atherosclerosis Calcinosis Carotid Intima-Media Thickness Cholesterol, beta-Lipoprotein Clinical Laboratory Services Complete Blood Count Comprehensive Metabolic Panel Congestive Heart Failure Coronary Arteriosclerosis Desiccation Disease Progression Dyslipidemias Estradiol Glucose High Blood Pressures Human Follicle Stimulating Hormone Hypertriglyceridemia Index, Body Mass Lipids Menopause Menstruation Mood Myocardial Infarction Obesity, Morbid Placebos Plasma Pressure, Diastolic Progesterone Sleeplessness Sweat Systolic Pressure Thromboembolism Thyrotropin Triglycerides Ultrasonography Vagina Woman
4
Comprehensive Health Assessment of Childhood Cancer Survivors
The study design and cohort characteristics of SJLIFE have been described previously [5 (link)]. Briefly, SJLIFE is an IRB-approved institutional cohort study at SJCRH with medical, physical, psychosocial, and neurocognitive assessments conducted to characterize health-related outcomes among adult survivors of childhood cancer [5 (link)]. Eligible participants who comprise the source population include living individuals 18 years of age or older who were treated for a pediatric malignancy at SJCRH, and who were diagnosed at least 10 years before enrollment [5 (link)]. Individuals who consent to participation in SJLIFE undergo a core battery of evaluations including history and physical examination with resting heart rate, blood pressure, and 12-lead electrocardiography, and laboratory assessments including a complete blood count/differential, comprehensive metabolic panel, urinalysis, and physical performance assessment including formal evaluations of anthropometrics, body composition, aerobic capacity, sensation, flexibility, balance, muscle strength, mobility, and gross and fine motor function. In addition participants received risk-directed clinical and laboratory evaluations according to the Children’s Oncology Group Long Term Follow-up Guidelines [13 (link),14 ].
Ojha R.P., Oancea S.C., Ness K.K., Lanctot J.Q., Srivastava D.K., Robison L.L., Hudson M.M, & Gurney J.G. (2012). Assessment of Potential Bias From Non-Participation in a Dynamic Clinical Cohort of Long-Term Childhood Cancer Survivors: Results From the St. Jude Lifetime Cohort Study. Pediatric blood & cancer, 60(5), 856-864.
Publication 2012
Adult Blood Pressure Body Composition Child Complete Blood Count Comprehensive Metabolic Panel Electrocardiography, 12-Lead Exercise, Aerobic Malignant Neoplasms Muscle Strength Neoplasms Physical Examination Range of Motion, Articular Rate, Heart Survivors of Childhood Cancer Urinalysis
5
Characterizing RA Treatment Patterns
We extracted the following information from the VA databases: rehabilitation visits (physical and occupational therapy), rheumatology visits, plain radiographs (hand, wrist, foot, ankle and cervical spine), extra-articular manifestations (pulmonary, soft tissue nodules, Felty's syndrome and Sjogren's syndrome), number of inflammatory marker (CRP and ESR) tests, number of platelet counts and chemistry panels ordered, rheumatoid factor testing, joint surgery (hand, wrist, knee, foot, ankle, elbow, cervical spine and shoulder) and DMARD use. The administrative study data period included both the one-year (1 July 1999 to 29 June 2000) and two-year (1 July 1 1998 to 29 June 2000) period before the one-year chart review study period.
Each physical therapy and occupational therapy visit was counted as a rehabilitation visit. Tests for CRP and ESR were aggregated into one category. Tests performed on the same day counted as separate tests. The number of hand, wrist, foot, ankle and cervical spine radiographs were also added together into one category. Three methods were used to count the number of prescriptions in a given year. First, we counted the total number of prescriptions (including repeat prescriptions) for the following 10 medications: auranofin, aurothioglucose, azathioprine, cyclosporine, etanercept (Enbrel, Amgen), hydroxychloroquine, infliximab (Remicade, Centocor), leflunomide, methotrexate and sulfasalazine (adalimumab, abatacept and rituximab were not yet available for RA). For the second method, prescriptions for each DMARD were counted once and added to obtain the total number of different DMARDs. For the third method, synthetic DMARDs and biological DMARDs were counted separately. Prescription for each type of DMARD was counted only once and then added together to obtain the total number of different synthetic DMARDs and biological DMARDs.
Ting G., Schneeweiss S., Scranton R., Katz J.N., Weinblatt M.E., Young M., Avorn J, & Solomon D.H. (2008). Development of a health care utilisation data-based index for rheumatoid arthritis severity: a preliminary study. Arthritis Research & Therapy, 10(4), R95.
Full text: Click here
Publication 2008
Abatacept Adalimumab Ankle Antirheumatic Drugs, Disease-Modifying Auranofin Aurothioglucose Azathioprine Biopharmaceuticals Cervical Vertebrae Comprehensive Metabolic Panel Cyclosporine Elbow Enbrel Etanercept Felty Syndrome Foot Hydroxychloroquine Inflammation Infliximab Joints Knee Joint Leflunomide Methotrexate Operative Surgical Procedures Pharmaceutical Preparations Physical Examination Platelet Counts, Blood Rehabilitation Remicade Rheumatoid Factor Rituximab Shoulder Sjogren's Syndrome Sulfasalazine Therapies, Occupational Therapy, Physical Tissues Wrist Joint X-Rays, Diagnostic

Most recents protocols related to «Comprehensive Metabolic Panel»

1
Liver Fibrosis Assessment via Serum Biomarkers

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2023
Albumins Aspartate Blood Platelets Comprehensive Metabolic Panel D-Alanine Transaminase Diabetes Mellitus Diagnosis Fibrosis Fibrosis, Liver Hypersensitivity Injuries Lavandula angustifolia Liver Liver Cirrhosis Serum Transferase
2
Cardiovascular Risk Factors Assessment and Framingham Risk Score
At baseline, CVRFs were classified during the HABS‐HD consensus review based on lab values, objective measures, self‐report, and current medication use.16 We defined hypertension as at least two readings of systolic blood pressure ≥140 mm Hg, diastolic blood pressure ≥90 mm Hg, or with a medical history and use of medications. We defined diabetes as hemoglobin A1c (HbA1c) ≥ 6.5% or with a medical history and use of medications. We defined dyslipidemia as low‐density lipoprotein (LDL) cholesterol ≥120 mg/dL, total cholesterol ≥240 mg/dL, triglycerides ≥200 mg/dL, or with a medical history and use of medications. Cigarette smoking was based on self‐reported current smoking. We used height and weight from the baseline exam to calculate body mass index (BMI) and defined obesity as a BMI ≥30 kg/m2. Participants underwent a collection of fasting blood at baseline, which was then assayed for a comprehensive metabolic panel, lipid panel, and HbA1c. Information on systolic and diastolic blood pressure, HbA1c, height and weight, LDL cholesterol, total cholesterol, high‐density lipoprotein (HDL) cholesterol, and triglycerides were collected at the baseline exam.
We assessed aggregated CVRF burden using the Framingham Risk Score (FRS),25 a sex‐specific algorithm based on age, total cholesterol, HDL cholesterol, systolic and diastolic blood pressures, smoking, and diabetes. FRS was initially developed to assess risk of coronary heart disease (CHD),25, 26 and has been shown to be associated with cognitive decline and brain pathology.27, 28, 29 We defined low, intermediate, and high FRS as having 10‐year CHD risk of <10% (female FRS <10; male FRS <6), 10% to 19% (female FRS 10‐14; male FRS 6‐8), and ≥ 20% (female FRS ≥15 male FRS ≥9), respectively.25
Jiang X., O'Bryant S.E., Johnson L.A., Rissman R.A, & Yaffe K. (2023). Association of cardiovascular risk factors and blood biomarkers with cognition: The HABS‐HD study. Alzheimer's & Dementia : Diagnosis, Assessment & Disease Monitoring, 15(1), e12394.
Publication 2023
BLOOD Brain Cholesterol Cholesterol, beta-Lipoprotein Comprehensive Metabolic Panel Diabetes Mellitus Disorders, Cognitive Dyslipidemias Heart Disease, Coronary Hemoglobin A, Glycosylated High Blood Pressures High Density Lipoprotein Cholesterol Index, Body Mass Lipids Low-Density Lipoproteins Males Obesity Pharmaceutical Preparations Pressure, Diastolic Systole Systolic Pressure Triglycerides Woman
3
Epigenomic Biomarkers in HIV-Associated HCC
This prospective study included a cohort of adults with newly diagnosed HCC with and without HIV enrolled in an NCI-funded study examining epigenomic biomarkers associated with HIV-associated HCC (Award number U54CA221205). Subjects with HCC were recruited between August 2018 and November 2021 from the Hepatology clinics and inpatients wards of both the Jos University Teaching Hospital (JUTH) and Lagos University Teaching Hospitals (LUTH), and their affiliated sites in Nigeria.
Inclusion criteria were: a) ≥18yrs; b) confirmed to have HCC diagnosed by ultrasound and computed tomography (CT) scan. Exclusion criteria were: a) other known primary or secondary malignancy either currently or within the past 5 years. HCC was diagnosed based on radiologic criteria using triple phase CT according to the AASLD 2018 guidelines [15 (link)], which was offered to all patients who had a ≥1cm nodule on ultrasound and/or risk factors for HCC (i.e. HIV, HBV, HCV infection or cirrhosis of any etiology), and/or other symptoms and signs suggestive of HCC. CT findings of arterial phase hyperenhancement and washout during the portal venous phase were considered diagnostic. A liver biopsy was not required for diagnosis, and was not performed in any of the study subjects.
All study subjects confirmed with HCC by CT were provided with information about the study and asked to sign an informed consent. At their enrollment visit, participants underwent a physical exam by the study physician and laboratory testing for HIV (ELISA and Western Blot); complete blood count (CBC), comprehensive chemistry panel including albumin, total bilirubin, aspartate aminotransferase (AST), alanine aminotransferase (ALT), viral serology including hepatitis B surface antigen (HBsAg) and antibody (anti-HBs) and HCV antibody (anti-HCV) using Lumi Quick diagnostics rapid test kits, and alpha-fetoprotein (AFP). Plasma samples were also collected for methylomic analysis. Patients who were confirmed HIV seropositive, also had CD4+ T cell count (flow cytometry (Partec GmbH, Munster, Germany), and HIV RNA Roche Ampliprep TaqMan (Roche Diagnostics Germany; lower limit of detection (LLD) of 20 cp/ml) testing performed and were referred immediately to the HIV care and treatment clinic at their respective institutions for further treatment and care. Confirmatory HBV and HCV viral load testing on stored specimens was performed on all HBsAg and anti-HCV positive participants using the Cepheid GeneXpert® system. Participants received the usual care and treatment for HCC, HIV, viral hepatitis and other health conditions, according to Nigerian national and international guidelines [16 , 17 (link)]. Sorafenib is offered to eligible patients with advanced disease and Child Pugh Turcotte (CPT) A where available. However, none of the study participants in the study received sorafenib or any other interventional therapies due to lack of access and/or high cost of the medication.
Davwar P.M., Okeke E., Duguru M., Nyam D., Bell K., Odeghe E.A., Oyeleke G., Lesi O.A., Singh R., Kim K.Y., Imade G., Akanmu A.S., Sagay A.S., Ogunsola F.T., Peters M.G., Roberts L.R., Hou L., Murphy R.L, & Hawkins C.A. (2023). Hepatocellular carcinoma presentation and prognosis among Nigerian adults with and without HIV. PLOS ONE, 18(3), e0282539.
Full text: Click here
Publication 2023
Adult Albumins alpha-Fetoproteins Antibodies Arteries Aspartate Transaminase Bilirubin Biological Markers Biopsy CD4+ Cell Counts Child Comprehensive Metabolic Panel D-Alanine Transaminase Diagnosis Enzyme-Linked Immunosorbent Assay Flow Cytometry Hepatitis B Surface Antigens Hepatitis C Antibodies Hepatitis Viruses Inpatient Liver Liver Cirrhosis Malignant Neoplasms Patients Physical Examination Physicians Plasma Radionuclide Imaging Reagent Kits, Diagnostic Sorafenib Ultrasonics Veins, Portal Western Blotting X-Ray Computed Tomography
4
Stimulation of C5 Ketogenesis by C7
Group C subjects received baseline analytical measurements (comprehensive metabolic panel, complete blood count, lipid panel, lactate, β-hydroxybutyrate, β-ketopentanoate and β-hydroxypentanoate) and physical examination. They then observed an overnight fast. C7 was calculated at a daily dose of 45% of daily caloric intake. The following morning, two doses were administered at approximately 6 AM (before breakfast) and 10 AM (before lunch), each containing ¼ of the total daily dose. Before lunch, at 12–1 PM, blood was collected for determination of ketone bodies as described31 (link), approximately 21 h after the baseline analysis. Figure 2 illustrates this experimental sequence.

Stimulation of C5 ketogenesis by C7. Plasma levels of C5 ketones before and after two C7 doses. Top and middle panels illustrate C5 ketone values before and after an overnight fasting period followed by two C7 doses. The baseline (pre-C7) values were obtained at 2–2:30 PM. Two C7 doses (each ¼ of the MTD) were administered approximately at 6 AM and 10 AM. The only morning meal was breakfast approximately at 8 AM. Each color symbol and time identifies one individual.

Málaga I., Avila A., Primeaux S., Kallem R.R., Roe C.R., Putnam W.C., Park J.Y., Shinnar S., Ahn C, & Pascual J.M. (2023). Maximum dose, safety, tolerability and ketonemia after triheptanoin in glucose transporter type 1 deficiency (G1D). Scientific Reports, 13, 3465.
Full text: Click here
Publication 2023
BLOOD Complete Blood Count Comprehensive Metabolic Panel Hydroxybutyrates Ketone Bodies Ketones Lactates Lipids Physical Examination Plasma
5
Evaluating ASO Activity in Mice
All experiments measuring ASO activity in animals were approved by the Institutional Animal Care and Use Committee of University of California, Irvine. Six- to eight-week old, male Balbc/J mice were purchased from the Jackson Laboratory and acclimated to the university vivarium for at least 7 days prior to experimentation. Mice were housed under a 12 h light/dark cycle at 20–22°C in groups of 2–4. Cages contained 1/8′ corncob bedding (7092A, Envigo, Huntingdon, UK) enriched with ∼6 g of cotton fiber nestlets (Ancare, Corp., Bellmore, NY). Mice were fed the vivarium stock diet (chow, 2020x, Envigo). Access to food and water was ad libitum. For oral administration of SH-BC-893, polypropylene feeding tubes (20 g × 38 mm; Instech Laboratories Inc., Plymouth, PA) were used to dose 120 mg/kg of SH-BC-893 dissolved in H2O (stock = 24 mg/ml). To aid gavage by inducing salivation, feeding tubes were dipped into a 1 g/ml sucrose solution immediately prior to treatment. For subcutaneous administration, ASOs were dissolved in PBS at a concentration such that 10 ml/kg was administered using a 27 G needle. For blood chemistry analysis, blood was collected by decapitation from nine-week old male Balbc/J mice. Serum was separated from whole blood in a SST-MINI tube with clot activator gel (Greiner, cat# 450571VET). Serum samples were sent to IDEXX Bioanalytics for a comprehensive chemistry panel (cat# 6006).
Finicle B.T., Eckenstein K.H., Revenko A.S., Anderson B.A., Wan W.B., McCracken A.N., Gil D., Fruman D.A., Hanessian S., Seth P.P, & Edinger A.L. (2023). Simultaneous inhibition of endocytic recycling and lysosomal fusion sensitizes cells and tissues to oligonucleotide therapeutics. Nucleic Acids Research, 51(4), 1583-1599.
Full text: Click here
Publication 2023
Administration, Oral Animals BLOOD Blood Chemical Analysis Clotrimazole Comprehensive Metabolic Panel Decapitation Diet Food Hematologic Tests Institutional Animal Care and Use Committees Males Mice, House Needles Polypropylenes Serum Sialorrhea Suby's G solution Sucrose Tube Feeding

Top products related to «Comprehensive Metabolic Panel»

1
Amplicor by Roche
Sourced in United States, Switzerland, Italy, China, Canada
Amplicor is a lab equipment product designed for nucleic acid amplification. It is a fully automated system used for the detection and quantification of target DNA or RNA sequences.
2
Vacutainer by BD
Sourced in United States, United Kingdom, Brazil, Germany, Canada, France, Spain, Switzerland, Italy, Australia, New Zealand, Sweden, Belgium, Ireland, South Sudan, Denmark, Mexico, Jersey, Austria, Japan, India
The BD Vacutainer is a blood collection system used to collect, process, and preserve blood samples. It consists of a sterile evacuated glass or plastic tube with a closure that maintains the vacuum. The Vacutainer provides a standardized method for drawing blood samples for laboratory analysis.
3
Piccolo general chemistry 13 panel discs by Abaxis
Sourced in United States
The Piccolo General Chemistry 13 Panel discs are a diagnostic lab equipment product designed for comprehensive metabolic panel testing. The discs provide an automated and efficient way to analyze multiple analytes, including electrolytes, kidney and liver function markers, and other key chemical indicators, from a single sample. The product is intended to support clinical decision-making by providing accurate and reliable test results.
4
Piccolo xpress chemistry analyzer by Abaxis
Sourced in United States
The Piccolo Xpress Chemistry Analyzer is a compact, automated in-vitro diagnostic device designed for the analysis of various chemical components in biological samples. The core function of this equipment is to perform rapid and accurate measurements of a panel of clinical chemistry analytes from a small sample volume.
5
Piccolo general chemistry 13 panel by Abaxis
Sourced in United States
The Piccolo general chemistry 13 panel is a laboratory equipment product offered by Abaxis. It is designed to perform a comprehensive panel of general chemistry tests. The device provides analytical results for 13 key biomarkers in a single sample. The core function of the Piccolo general chemistry 13 panel is to enable efficient and accurate testing across a range of common clinical analytes.
6
General chemistry 13 panel by Abaxis
Sourced in United States
The General Chemistry 13 panel is a comprehensive diagnostic tool designed to provide a broad analysis of an individual's overall health status. This panel includes the measurement of various biochemical markers such as electrolytes, liver enzymes, kidney function indicators, and other related parameters. The General Chemistry 13 panel is intended to assist healthcare professionals in assessing an individual's general health and detecting potential imbalances or abnormalities that may require further investigation or treatment.
7
Hemavet 950fs by Drew Scientific
Sourced in United States, United Kingdom
The Hemavet 950FS is a compact and automated hematology analyzer designed for veterinary use. It provides a comprehensive analysis of complete blood count (CBC) parameters, including red blood cells, white blood cells, and platelet counts, as well as related indices. The device uses advanced technology to deliver accurate and reliable results quickly.
8
Procyte dx analyzer by IDEXX
Sourced in Germany, United States, Montenegro
The IDEXX ProCyte DX analyzer is a veterinary hematology instrument that provides comprehensive blood cell analysis. It utilizes advanced technology to deliver accurate and reliable results for various hematological parameters.
9
Piccolo point of care analyzer by Abaxis
Sourced in United States
The Piccolo point-of-care analyzer is a compact, portable device designed for rapid in-vitro diagnostic testing. It utilizes optical technology to analyze small sample volumes and provide quick results on various clinical chemistry parameters.
10
Piccolo xpress chemistry analyzer by Abbott
Sourced in United States
The Piccolo Xpress Chemistry Analyzer is a compact, point-of-care instrument designed for rapid and accurate analysis of a range of clinical chemistry parameters. It utilizes a single-use reagent disc to perform multiple tests from a small sample volume, providing fast and reliable results.

More about "Comprehensive Metabolic Panel"

The Comprehensive Metabolic Panel (CMP) is a widely used laboratory test that provides a comprehensive assessment of an individual's metabolic status.
This panel measures a variety of serum chemicals and electrolytes, including glucose, kidney and liver function markers, and other key metabolic indicators.
The CMP is often employed as a screening tool to evaluate overall health and detect potential imbalances or underlying medical conditions.
Clinicians may order a CMP as part of a routine checkup or to investigate specific symptoms or concerns.
The test results can offer valuable insights into a patient's metabolic profile and help guide further diagnostic evaluation and treatment planning.
Optimizing CMP research through techniques like PubCompare.ai can enhance the reproducibility and accuracy of these important clinical measurements.
Synonyms and related terms for the CMP include the General Chemistry 13 panel, which is a similar test that measures the same set of metabolic markers.
The Piccolo General Chemistry 13 Panel discs and the Piccolo Xpress Chemistry Analyzer are examples of laboratory equipment used to perform the CMP.
The Hemavet 950FS and IDEXX ProCyte DX analyzer are other instruments that can be used for related blood tests.
Abbreviations commonly used for the Comprehensive Metabolic Panel include CMP and GC13.
The BD Vacutainer is a type of blood collection tube often used for CMP testing.
By leveraging the insights from these related terms and technologies, researchers can optimize their CMP research and enhance the reliability and accuracy of their findings.